Latest Safety News

GreenHy2 Limited has strengthened its cash position to $1.58 million while progressing its flagship Telstra hydrogen storage project and expanding its battery technology portfolio.

Biotron Limited has successfully raised $1.27 million through an entitlement issue to fund its antiviral drug development, including a promising Hepatitis B compound that cleared its initial animal safety study.

Minbos Resources has secured key financing and made significant construction strides on its Angolan phosphate fertilizer plant, while rolling out promising new fertilizer blends to support local agriculture.

Radiopharm Theranostics reports significant progress in its oncology radiopharmaceutical pipeline, including FDA Fast Track designation and dose escalation approvals, supported by a solid cash runway through mid-2026.

Prescient Therapeutics has raised $6.8 million through a Share Purchase Plan to fund the Phase 2 development of its novel cancer therapy PTX-100, while launching a discounted placement to sophisticated investors.

Omnia Metals Group has completed a targeted 941-metre drilling program at its Salt Creek Project, while announcing key leadership changes and preparing for an upcoming General Meeting.

Syntara Limited has initiated dosing in its Phase 1a/b trial for SNT-9465, a topical drug targeting hypertrophic scars, aiming to offer a non-invasive alternative to current treatments. Results expected in early 2026 could pave the way for global development and FDA approval.

Beacon Minerals has completed an 8-hole diamond drilling program at its Iguana deposit, revealing significant high-grade gold mineralisation and confirming geotechnical stability for pit designs. These findings set the stage for an updated resource model and future development plans.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Bannerman Energy reports robust progress on its Etango Uranium Project, achieving key construction milestones and securing A$85 million in fresh equity to fuel its path to a Final Investment Decision.

Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.

Greatland Resources reports strong FY25 results with gold and copper production meeting guidance and costs significantly below expectations. The company advances Havieron feasibility and outlines ambitious FY26 growth capital plans to extend mine life and boost production.